Peptide News Digest

#Ziltivekimab-Context

2 stories

Industry · View digest

Novo Nordisk Capital Markets Day Weekend Preview: CEO Mike Doustdar Frames Monday London Reset Around 'Obesity Is Not a Zero-Sum Game' and 'The Novo Way' Culture Framework

Weekend previews of the Monday September 21, 2026 Novo Capital Markets Day in London (webcast live from 09:00 BST / 10:00 CET, running to 15:30 BST / 16:30 CET) landed Saturday and Sunday framing CEO Mike Doustdar's most direct commentary to date on the semaglutide-vs-tirzepatide franchise dynamic. In a Reuters interview released Friday September 18, Doustdar characterized the obesity market as not a 'zero-sum game' as patients 'crave optionality,' rejecting the Morgan Stanley Underweight thesis (September 11 downgrade, DKK 250 target) that Wegovy's U.S. share erosion is structural. Doustdar's 'Novo Way' culture framework announced with the September 14 rebrand emphasizes customer focus, competitiveness, clarity, and care. Sell-side previews (TIKR, Bloomberg, Kontra Invest, TradingKey) frame CMD priorities as: managing the 2031 semaglutide loss of exclusivity, U.S. Wegovy pill script trajectory (>5 million total prescriptions as of August), the CagriSema U.S. obesity decision path (late 2026), the ziltivekimab HERMES/ATHENA terminations, the $1.4 billion Orbis Medicines Sept 17 macrocycle deal, and the Sept 16 Anthropic Claude Science R&D collaboration. NVO shares closed Friday at $42.97 (-0.23% weekly).

Industry · View digest

Novo Nordisk Rebrands as 'Novo' With New 'Lasting Health Starts Now' Tagline and 'The Novo Way' Culture Framework Ahead of September 21 London Capital Markets Day

Novo Nordisk (NYSE: NVO; Copenhagen: NOVO-B) announced Monday September 14, 2026 the rollout of its updated corporate identity: the operating brand is now simply 'Novo' with the tagline 'Lasting health starts now' plus a new culture framework called 'The Novo Way,' anchored by a refreshed version of the historic Apis bull logo. The legal entity name Novo Nordisk A/S is unchanged, and the NYSE ticker (NVO) and Copenhagen (NOVO-B) tickers remain. CEO Mike Doustdar is expected to detail the strategic backing for the rebrand at the September 21 Capital Markets Day in London — the first Novo Capital Markets Day since Doustdar was named CEO and following the Morgan Stanley Underweight downgrade on Friday September 11 (DKK 250 target, semaglutide patent cliff concerns), Barclays trim from DKK 310 to DKK 300, and HSBC target raise to DKK 320 (Hold). The rebrand pairs with an operational push to regain U.S. Wegovy/Ozempic prescription share against Lilly's tirzepatide franchise, plus the September 16 Anthropic Claude Science R&D collaboration, September 7 STEP Young pediatric semaglutide win, and September 4-7 ziltivekimab HERMES + ATHENA heart-failure trial terminations that have narrowed the non-GLP-1 diversification story.